This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related letter  • Related articles  • Similar articles in this journal  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

I have 3 comments on the article by Grundy et al¹ regarding the use of extended-release niacin for the treatment of dyslipidemia with type 2 diabetes mellitus. First, the references of the article include major errors that created significant confusion. In fact, 9 of the 26 listed references (reference numbers 7, 14, 17, 18, 19, 20, 22, 23, and 24) were either misplaced or irrelevant to the content of the corresponding text. For example, on page 1569, the authors reported the effects of the 0.9% reduction in hemoglobin A_1c on diabetic vascular complications in the United Kingdom Prospective Diabetes Study (UKPDS), stating reference number 7 as the corresponding reference. However, reference number 7 on page 1576 was related to a study published in 1987 about the determinants of coronary artery disease in juvenile-onset diabetes. On the other hand, the UKPDS was published in 1998 and only involved patients with type . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTER

Efficacy, Safety, and Tolerability of Once-Daily Niacin for the Treatment of Dyslipidemia Associated With Type 2 Diabetes: Results of the Assessment of Diabetes Control and Evaluation of the Efficacy of Niaspan Trial
Scott M. Grundy, Gloria Lena Vega, Mark E. McGovern, Brian R. Tulloch, David M. Kendall, David Fitz-Patrick, Om P. Ganda, Robert S. Rosenson, John B. Buse, David D. Robertson, John P. Sheehan, and for the Diabetes Multicenter Research Group
Arch Intern Med. 2002;162(14):1568-1576.
ABSTRACT | FULL TEXT  

RELATED ARTICLES

The Use of Niacin in Diabetes Mellitus
Scott M. Grundy
Arch Intern Med. 2003;163(3):370.
EXTRACT | FULL TEXT  

Efficacy, Safety, and Tolerability of Once-Daily Niacin for the Treatment of Dyslipidemia Associated With Type 2 Diabetes: Results of the Assessment of Diabetes Control and Evaluation of the Efficacy of Niaspan Trial
Scott M. Grundy, Gloria Lena Vega, Mark E. McGovern, Brian R. Tulloch, David M. Kendall, David Fitz-Patrick, Om P. Ganda, Robert S. Rosenson, John B. Buse, David D. Robertson, John P. Sheehan, and for the Diabetes Multicenter Research Group
Arch Intern Med. 2002;162(14):1568-1576.
ABSTRACT | FULL TEXT